Back to Rankings

QURE

uniQureA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-11
View Chart
Current thesis
The company source supports a still-constructive monitoring thesis: AMT-130 retains an active regulatory path, the UK filing remains targeted for Q3 2026, AMT-260 has a dated June catalyst, and cash runway into 2H29 reduces immediate financing pressure [#8-K-2026-05-05].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -5.3.
What can break
AMT-191 has dose-limiting toxicity concerns: additional mid- and high-dose dosing remains paused pending evaluation of asymptomatic Grade 3 liver enzyme elevations in two patients [#8-K-2026-05-05].
Momentum
92
Value
41
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $30.00 · Bull $36.00 · Bear $20.00
Data freshness
Prices
As of 2026-06-11
Fundamentals
As of 2026-06-10 • Vendor: Data Vendor v1
Scores
As of 2026-06-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-11
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $28.67
Why
Momentum92 · Δ7d -5.3
Value41 · Δ7d -0.1
Sentiment54 · Δ7d +6.9
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
92
34% active weight
Current posture
7d trendSoftening
Δ7d
-5.3
Δ21d
-6.4
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.1
Sentiment
54
33% active weight
Current posture
7d trendImproving
Δ7d
+6.9
Δ21d
-10.7
Why this grade

Composite grade A. Momentum 92.5 / Value 41.0 / Sentiment 54.5

Fundamentals (TTM)
As of 2026-06-10
Market Cap
$1.68B
Beta
0.67
Shares Out
62.29M
P/E (TTM) · Derived
-7.8
P/S (TTM)
89.50
P/FCF (TTM) · Derived
-9.43
Rev YoY
+61.8%
EPS YoY
-51.1%
Gross Margin
+88.1%
Op Margin
-1143.2%
Net Debt
$118.73M
Current Ratio
7.12
As of 2026-06-11 • Updated nightlySource: Internal modelMethodology